A Case Report of Long‐term Remission of Ulcerative Colitis After Lymphocyto‐plasmapheresis

Abstract:  Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colorectum, with mucosal infiltration by activated leukocytes, which are the result of complex interactions between lymphocytes, antigen, and dendritic cells (DCs). We carried out lymphocyto‐plasmapheresis (LCPA) in a UC patient with the aim of removing lymphocytes, DCs and inflammatory cytokines (ICKs). A 42‐year‐old female with UC in moderate activity phase was submitted to 5 weekly LCPA treatments. Before and after LCPA we monitored: (i) the percentage of T, B, NK lymphocytes, monocytes, and peripheral blood lymphoid and myeloid DCs; (ii) the T lymphocyte subpopulations; (iii) the ICKs; and (iv) the immune complexes (IC). We achieved the interruption of all pharmacological therapies, and so far the clinical and histological remission has lasted for 24 months. The flow cytometric assessment of the leukocyte subpopulations did not show any relevant variation of their numbers after LCPA, while TNFα, IL‐6, IL‐12 and serum IgG‐C1q ICs decreased. In the present case, the contemporary depletion of plasma, lymphocytes and DCs, allowed LCPA to emerge as an efficient alternative to UC pharmacological therapy without affecting the number of white blood cells, DCs and leukocyte subpopulations that were assessed. Further studies are needed both to address LCPA mechanism of action and optimal apheresis protocol, and to compare this form of therapy to a placebo control group. 

[1]  I. Bjarnason,et al.  Adacolumn for selective leukocytapheresis as a non‐pharmacological treatment for patients with disorders of the immune system: An adjunct or an alternative to drug therapy? , 2005, Journal of clinical apheresis.

[2]  A. Munakata,et al.  Leukocytapheresis in Ulcerative Colitis: Results of a Multicenter Double-Blind Prospective Case-Control Study with Sham Apheresis as Placebo Treatment , 2005, The American Journal of Gastroenterology.

[3]  K. Sawada Leukocytapheresis as an Adjunct to Conventional Medication for Inflammatory Bowel Disease , 2003, Diseases of the colon and rectum.

[4]  M. Onji,et al.  Depletion and Decreased Function of Antigen-Presenting Dendritic Cells Caused by Lymphocytapheresis in Ulcerative colitis , 2003, Diseases of the colon and rectum.

[5]  T. Hibi,et al.  Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. , 2003, Current pharmaceutical design.

[6]  T. Muto,et al.  Leukocyte Apheresis Using a Centrifugal Cell Separator in Refractory Ulcerative Colitis: A Multicenter Open Label Trial , 2002 .

[7]  T. Muto,et al.  Leukocyte apheresis using a centrifugal cell separator in refractory ulcerative colitis: a multicenter open label trial. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[8]  H. Hashimoto,et al.  Current topics on cytapheresis technologies. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[9]  M. Ono,et al.  A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. , 1997, Internal medicine.

[10]  R. Modigliani,et al.  Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. , 1994, Gastroenterology.

[11]  K. Groshart,et al.  The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. , 1989, Journal of clinical gastroenterology.

[12]  Matts Sg,et al.  THE VALUE OF RECTAL BIOPSY IN THE DIAGNOSIS OF ULCERATIVE COLITIS1 , 1961 .

[13]  S G MATTS,et al.  The value of rectal biopsy in the diagnosis of ulcerative colitis. , 1961, The Quarterly journal of medicine.

[14]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .